Alexandra Antunes

Dr. Alexandra Antunes

Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2008 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
AWAna Rita Elias Brás Würschig
Ana Rita Elias Brás Würschig
JNJoão Paulo Paulo Noronha
João Paulo Paulo Noronha
Alexandra AntunesAlexandra Antunes
Alexandra Antunes
MCM. Margarida Cardoso
M. Margarida Cardoso
ASAndreas Schönhals
Andreas Schönhals
NCNatalia T. Correia
Natalia T. Correia

7 May 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IMInês L. Martins
Inês L. Martins
CCCatarina Charneira
Catarina Charneira
Valentina GandinValentina Gandin
Valentina Gandin
JSJoao Silva
Joao Silva
GJGonçalo Justino
Gonçalo Justino
Alexandra AntunesAlexandra Antunes
Alexandra Antunes

1 August 2013 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ESEdson dos A. dos Santos
Edson dos A. dos Santos
EHErnest Hamel
Ernest Hamel
RBRuoli Bai
Ruoli Bai
JBJames C. Burnett
James C. Burnett
CTCamila Santos Suniga Tozatti
Camila Santos Suniga Tozatti
DLDênis Pires de Lima
Dênis Pires de Lima

20 November 2019 in Crystal Growth & Design
Verified
Journal Article
Closed access
SQSilvia Quaresma
Silvia Quaresma
Vânia AndréVânia André
Vânia André
Alexandra AntunesAlexandra Antunes
Alexandra Antunes
SVSérgio Vilela
Sérgio Vilela
GAGeorgiana Amariei
Georgiana Amariei
MDMaria Teresa Duarte
Maria Teresa Duarte

8 May 2019 in ACS Applied Bio Materials
Verified
Journal Article
Open access
Vânia AndréVânia André
Vânia André
ASAndré Ramires Ferreira da Silva
André Ramires Ferreira da Silva
AFAuguste Fernandes
Auguste Fernandes
RFRaquel Frade
Raquel Frade
CGCatarina Garcia
Catarina Garcia
MDMaria Teresa Duarte
Maria Teresa Duarte
The development of Metal-Organic Frameworks enclosing ac-tive pharmaceutical ingredients is of considerable interest, as their use in controlled drug release and delivery is very promis-ing. Although nalidixic acid is an antibiotic with a broad spec-trum of biological applications, effective mainly against Gram-negative infections, its oral bioavailability is low due to poor solubility and slow dissolution. Herein, we report new Metal Organic Frameworks (BioMOFs) comprising nalidixic acid and divalent magnesium and manganese ions. These compounds showed adequate cytotoxicity and improved antimicrobial activ-ity, especially against Gram-negative bacteria. These BioMOFS are among the first examples containing active pharmaceutical ingredients as linkers. Importantly, it is shown that a remarka-ble increase of the antimicrobial activity of certain antibiotics may be achieved by delivering them in the form of BioMOFs.

19 October 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
ISInês Santos
Inês Santos
CRCristiano Ramos
Cristiano Ramos
CMCindy Mendes
Cindy Mendes
CSCatarina Sequeira
Catarina Sequeira
CTCatarina S. Tome
Catarina S. Tome
Jacinta SerpaJacinta Serpa
Jacinta Serpa
Ovarian cancer is the main cause of death from gynecological cancer, with its poor prognosis mainly related to late diagnosis and chemoresistance (acquired or intrinsic) to conventional alkylating and reactive oxygen species (ROS)-generating drugs. We and others reported that the availability of cysteine and glutathione (GSH) impacts the mechanisms of resistance to carboplatin in ovarian cancer. Different players in cysteine metabolism can be crucial in chemoresistance, such as the cystine/glutamate antiporter system Xc (xCT) and the H2S-synthesizing enzyme cystathionine β-synthase (CBS) in the pathway of cysteine catabolism. We hypothesized that, by disrupting cysteine metabolic flux, chemoresistance would be reverted. Since the xCT transporter is also able to take up selenium, we used selenium-containing chrysin (SeChry) as a plausible competitive inhibitor of xCT. For that, we tested the effects of SeChry on three different ovarian cancer cell lines (ES2, OVCAR3, and OVCAR8) and in two non-malignant cell lines (HaCaT and HK2). Results showed that, in addition to being highly cytotoxic, SeChry does not affect the uptake of cysteine, although it increases GSH depletion, indicating that SeChry might induce oxidative stress. However, enzymatic assays revealed an inhibitory effect of SeChry toward CBS, thus preventing production of the antioxidant H2S. Notably, our data showed that SeChry and folate-targeted polyurea dendrimer generation four (SeChry@PUREG4-FA) nanoparticles increased the specificity for SeChry delivery to ovarian cancer cells, reducing significantly the toxicity against non-malignant cells. Collectively, our data support SeChry@PUREG4-FA nanoparticles as a targeted strategy to improve ovarian cancer treatment, where GSH depletion and CBS inhibition underlie SeChry cytotoxicity.